Amicus Therapeutics Inc (FOLD) - Net Assets
Based on the latest financial reports, Amicus Therapeutics Inc (FOLD) has net assets worth $274.24 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($949.87 Million) and total liabilities ($675.63 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check FOLD tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $274.24 Million |
| % of Total Assets | 28.87% |
| Annual Growth Rate | N/A |
| 5-Year Change | -10.78% |
| 10-Year Change | -23.85% |
| Growth Volatility | 230.07 |
Amicus Therapeutics Inc - Net Assets Trend (2003–2025)
This chart illustrates how Amicus Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. See Amicus Therapeutics Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Amicus Therapeutics Inc (2003–2025)
The table below shows the annual net assets of Amicus Therapeutics Inc from 2003 to 2025. For live valuation and market cap data, see Amicus Therapeutics Inc stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $274.24 Million | +41.33% |
| 2024-12-31 | $194.04 Million | +21.15% |
| 2023-12-31 | $160.17 Million | +30.17% |
| 2022-12-31 | $123.05 Million | -59.97% |
| 2021-12-31 | $307.37 Million | +7.33% |
| 2020-12-31 | $286.38 Million | -39.89% |
| 2019-12-31 | $476.43 Million | +38.94% |
| 2018-12-31 | $342.91 Million | -2.82% |
| 2017-12-31 | $352.85 Million | -2.03% |
| 2016-12-31 | $360.15 Million | +3.54% |
| 2015-12-31 | $347.83 Million | +184.69% |
| 2014-12-31 | $122.18 Million | +167.05% |
| 2013-12-31 | $45.75 Million | -33.90% |
| 2012-12-31 | $69.22 Million | +133.91% |
| 2011-12-31 | $29.59 Million | -54.43% |
| 2010-12-31 | $64.93 Million | -9.60% |
| 2009-12-31 | $71.83 Million | +1.11% |
| 2008-12-31 | $71.04 Million | -31.22% |
| 2007-12-31 | $103.30 Million | +233.26% |
| 2006-12-31 | $-77.52 Million | -116.34% |
| 2005-12-31 | $-35.83 Million | -963.16% |
| 2004-12-31 | $4.15 Million | +178.69% |
| 2003-12-31 | $-5.28 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Amicus Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 275878700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.04 Million | 1.11% |
| Other Comprehensive Income | $24.11 Million | 8.79% |
| Other Components | $3.01 Billion | 1099.17% |
| Total Equity | $274.24 Million | 100.00% |
Amicus Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Amicus Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
LG Display Co Ltd
NYSE:LPL
|
$4.55 Billion |
|
CSN Mineração S.A
SA:CMIN3
|
$4.55 Billion |
|
Fortune Brands Innovations Inc.
NYSE:FBIN
|
$4.55 Billion |
|
Sabra Healthcare REIT Inc
NASDAQ:SBRA
|
$4.55 Billion |
|
Andon Health Co Ltd
SHE:002432
|
$4.55 Billion |
|
CNO Financial Group Inc
NYSE:CNO
|
$4.55 Billion |
|
JK Cement Limited
NSE:JKCEMENT
|
$4.55 Billion |
|
China Southern Power Grid Technology Co Ltd
SHG:688248
|
$4.54 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Amicus Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 194,045,000 to 274,241,000, a change of 80,196,000 (41.3%).
- Net loss of 27,110,000 reduced equity.
- Other comprehensive income increased equity by 19,014,000.
- Other factors increased equity by 88,292,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-27.11 Million | -9.89% |
| Other Comprehensive Income | $19.01 Million | +6.93% |
| Other Changes | $88.29 Million | +32.2% |
| Total Change | $- | 41.33% |
Book Value vs Market Value Analysis
This analysis compares Amicus Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 16.29x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2003-12-31 | $-17.15 | $14.49 | x |
| 2004-12-31 | $13.50 | $14.49 | x |
| 2005-12-31 | $-87.34 | $14.49 | x |
| 2006-12-31 | $-105.32 | $14.49 | x |
| 2007-12-31 | $7.80 | $14.49 | x |
| 2008-12-31 | $3.16 | $14.49 | x |
| 2009-12-31 | $3.18 | $14.49 | x |
| 2010-12-31 | $2.34 | $14.49 | x |
| 2011-12-31 | $0.86 | $14.49 | x |
| 2012-12-31 | $1.52 | $14.49 | x |
| 2013-12-31 | $0.89 | $14.49 | x |
| 2014-12-31 | $1.64 | $14.49 | x |
| 2015-12-31 | $3.16 | $14.49 | x |
| 2016-12-31 | $2.68 | $14.49 | x |
| 2017-12-31 | $2.30 | $14.49 | x |
| 2018-12-31 | $1.85 | $14.49 | x |
| 2019-12-31 | $1.98 | $14.49 | x |
| 2020-12-31 | $1.11 | $14.49 | x |
| 2021-12-31 | $1.13 | $14.49 | x |
| 2022-12-31 | $0.43 | $14.49 | x |
| 2023-12-31 | $0.54 | $14.49 | x |
| 2024-12-31 | $0.64 | $14.49 | x |
| 2025-12-31 | $0.89 | $14.49 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Amicus Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -9.89%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -4.27%
- • Asset Turnover: 0.67x
- • Equity Multiplier: 3.46x
- Recent ROE (-9.89%) is above the historical average (-72.30%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2003 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.24 Million |
| 2004 | -212.17% | 0.00% | 0.00x | 1.22x | $-9.22 Million |
| 2005 | 0.00% | 0.00% | 0.00x | 0.00x | $-16.39 Million |
| 2006 | 0.00% | 0.00% | 0.00x | 0.00x | $-38.59 Million |
| 2007 | -39.85% | -2307.57% | 0.01x | 1.62x | $-51.50 Million |
| 2008 | -55.40% | -262.95% | 0.12x | 1.81x | $-46.46 Million |
| 2009 | -9.14% | -10.20% | 0.75x | 1.19x | $-13.75 Million |
| 2010 | -84.60% | -5958.35% | 0.01x | 1.73x | $-61.43 Million |
| 2011 | -150.08% | -207.20% | 0.31x | 2.36x | $-47.37 Million |
| 2012 | -70.48% | -264.98% | 0.17x | 1.59x | $-55.71 Million |
| 2013 | -130.34% | -16427.82% | 0.00x | 2.79x | $-64.21 Million |
| 2014 | -56.41% | -5631.21% | 0.01x | 1.72x | $-81.14 Million |
| 2015 | -37.98% | 0.00% | 0.00x | 2.61x | $-166.90 Million |
| 2016 | -55.54% | -4034.73% | 0.00x | 2.88x | $-236.06 Million |
| 2017 | -80.49% | -769.03% | 0.06x | 1.78x | $-319.29 Million |
| 2018 | -101.77% | -382.48% | 0.12x | 2.30x | $-383.29 Million |
| 2019 | -74.80% | -195.56% | 0.21x | 1.78x | $-404.03 Million |
| 2020 | -96.67% | -106.12% | 0.29x | 3.10x | $-305.49 Million |
| 2021 | -81.49% | -81.98% | 0.34x | 2.94x | $-281.20 Million |
| 2022 | -192.26% | -71.85% | 0.45x | 5.89x | $-248.87 Million |
| 2023 | -94.64% | -37.96% | 0.51x | 4.86x | $-167.60 Million |
| 2024 | -28.91% | -10.62% | 0.67x | 4.05x | $-75.51 Million |
| 2025 | -9.89% | -4.27% | 0.67x | 3.46x | $-54.53 Million |
Industry Comparison
This section compares Amicus Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Amicus Therapeutics Inc (FOLD) | $274.24 Million | 0.00% | 2.46x | $4.55 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Amicus Therapeutics Inc
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha … Read more